We found that PRMT5 inhibition in combination with the DNA‐damaging chemotherapeutic drug CPT‐11 induced a dMMR‐like state, thereby enhancing cGAS‐STING pathway activation and anti‐tumor immune reprogramming, ultimately increasing the sensitivity to ICIs treatment in MSS CRC. Here, PRMT5 is linked to colorectal carcinoma.